The efficacy and safety in canaglifrozin therapy for diabetes complicated by non-alcoholic fatty liver disease.
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Canagliflozin (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Jul 2018 Status changed from active, no longer recruiting to completed.
- 03 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Nov 2016 Status changed from not yet recruiting to recruiting.